Biomolecules & Therapeutics

  • 제23권2호
  • /
  • Pages.189-194
  • /
  • 2015
  • /
  • 1976-9148(pISSN)
  • /
  • 2005-4483(eISSN)
한국응용약물학회 (The Korean Society of Applied Pharmacology)
권호 표지
DOI QR코드

DOI QR Code

Functional Significance of Cytochrome P450 1A2 Allelic Variants, P450 1A2*8, *15, and *16 (R456H, P42R, and R377Q)

  • Lim, Young-Ran (Department of Biological Sciences, Konkuk University) ;
  • Kim, In-Hyeok (Department of Biological Sciences, Konkuk University) ;
  • Han, Songhee (Department of Biological Sciences, Konkuk University) ;
  • Park, Hyoung-Goo (Department of Biological Sciences, Konkuk University) ;
  • Ko, Mi-Jung (Department of Biological Sciences, Konkuk University) ;
  • Chun, Young-Jin (College of Pharmacy, Chung-Ang University) ;
  • Yun, Chul-Ho (School of Biological Sciences and Technology, Chonnam National University) ;
  • Kim, Donghak (Department of Biological Sciences, Konkuk University)
  • 투고 : 2015.01.15
  • 심사 : 2015.01.29
  • 발행 : 2015.03.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

P450 1A2 is responsible for the metabolism of clinically important drugs and the metabolic activation of environmental chemicals. Genetic variations of P450 1A2 can influence its ability to perform these functions, and thus, this study aimed to characterize the functional significance of three P450 1A2 allelic variants containing nonsynonymous single nucleotide polymorphisms (P450 $1A2^*8$, R456H; $^*15$, P42R; $^*16$, R377Q). Variants containing these SNPs were constructed and the recombinant enzymes were expressed and purified in Escherichia coli. Only the P42R variant displayed the typical CO-binding spectrum indicating a P450 holoenzyme with an expression level of ~ 170 nmol per liter culture, but no P450 spectra were observed for the two other variants. Western blot analysis revealed that the level of expression for the P42R variant was lower than that of the wild type, however the expression of variants R456H and R377Q was not detected. Enzyme kinetic analyses indicated that the P42R mutation in P450 1A2 resulted in significant changes in catalytic activities. The P42R variant displayed an increased catalytic turnover numbers ($k_{cat}$) in both of methoxyresorufin O-demethylation and phenacetin O-deethylation. In the case of phenacetin O-deethylation analysis, the overall catalytic efficiency ($k_{cat}/K_m$) increased up to 2.5 fold with a slight increase of its $K_m$ value. This study indicated that the substitution P42R in the N-terminal proline-rich region of P450 contributed to the improvement of catalytic activity albeit the reduction of P450 structural stability or the decrease of substrate affinity. Characterization of these polymorphisms should be carefully examined in terms of the metabolism of many clinical drugs and environmental chemicals.

키워드

참고문헌

  1. Chen, S. and Zhou, D. (1992) Functional domains of aromatase cytochrome P450 inferred from comparative analyses of amino acid sequences and substantiated by site-directed mutagenesis experiments. J. Biol. Chem. 267, 22587-22594.
  2. Choi, S., Han, S., Lee, H., Chun, Y. J. and Kim, D. (2013) Evaluation of luminescent P450 analysis for directed evolution of human CYP4A11. Biomol. Ther. 21, 487-492. https://doi.org/10.4062/biomolther.2013.086
  3. Guengerich, F. P. (2003) Cytochromes P450, drugs, and diseases. Mol. Interv. 3, 194-204. https://doi.org/10.1124/mi.3.4.194
  4. Han, S., Choi, S., Chun, Y. J., Yun, C. H., Lee, C. H., Shin, H. J., Na, H. S., Chung, M. W. and Kim, D. (2012) Functional characterization of allelic variants of polymorphic human cytochrome P450 2A6 (CYP2A6*5, *7, *8, *18, *19, and *35). Biol. Pharm. Bull. 35, 394-399. https://doi.org/10.1248/bpb.35.394
  5. Han, S., Eun, C. Y., Han, J. S., Chun, Y. J., Kim, D. H., Yun, C. H. and Kim, D. (2009) Self-sufficient catalytic system of human cytochrome P450 4A11 and NADPH-P450 reductase. Biomol. Ther. 17, 156-161. https://doi.org/10.4062/biomolther.2009.17.2.156
  6. Kalow, W. and Tang, B. K. (1991) Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin. Pharmacol. Ther. 50, 508-519. https://doi.org/10.1038/clpt.1991.176
  7. Kemper, B. (2004) Structural basis for the role in protein folding of conserved proline-rich regions in cytochromes P450. Toxicol. Appl. Pharmacol. 199, 305-315. https://doi.org/10.1016/j.taap.2003.11.030
  8. Kim, D. and Guengerich, F. P. (2005) Cytochrome P450 activation of arylamines and heterocyclic amines. Annu. Rev. Pharmacol. Toxicol. 45, 27-49. https://doi.org/10.1146/annurev.pharmtox.45.120403.100010
  9. Kim, D., Wu, Z. L. and Guengerich, F. P. (2005) Analysis of coumarin 7-hydroxylation activity of cytochrome P450 2A6 using random mutagenesis. J. Biol. Chem. 280, 40319-40327. https://doi.org/10.1074/jbc.M508171200
  10. Lee, I. S. and Kim, D. (2011) Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes. Arch. Pharm. Res. 34, 1799-1816. https://doi.org/10.1007/s12272-011-1103-2
  11. Lundqvist, E., Johansson, I. and Ingelman-Sundberg, M. (1999) Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226, 327-338. https://doi.org/10.1016/S0378-1119(98)00567-8
  12. Park, H. G., Lim, Y. R., Han, S. and Kim, D. (2014) Expression and characterization of truncated recombinant human cytochrome P450 2J2. Toxicol. Res. 30, 33-38. https://doi.org/10.5487/TR.2014.30.1.033
  13. Ravichandran, K. G., Boddupalli, S. S., Hasermann, C. A., Peterson, J. A. and Deisenhofer, J. (1993) Crystal structure of hemoprotein domain of P450BM-3, a prototype for microsomal P450's. Science 261, 731-736. https://doi.org/10.1126/science.8342039
  14. Saito, Y., Hanioka, N., Maekawa, K., Isobe, T., Tsuneto, Y., Nakamura, R., Soyama, A., Ozawa, S., Tanaka-Kagawa, T., Jinno, H., Narimatsu, S. and Sawada, J. (2005) Functional analysis of three CYP1A2 variants found in a Japanese population. Drug Metab. Dispos. 33, 1905-1910.
  15. Sansen, S., Yano, J. K., Reynald, R. L., Schoch, G. A., Griffin, K. J., Stout, C. D. and Johnson, E. F. (2007) Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J. Biol. Chem. 282, 14348-14355. https://doi.org/10.1074/jbc.M611692200
  16. Smith, R. L., Idle, J. R., Mahgoub, A. A., Sloan, T. P. and Lancaster, R. (1978) Genetically determined defcts of oxidation at carbon centres of drugs. Lancet 1, 943-944.
  17. Soyama, A., Saito, Y., Hanioka, N., Maekawa, K., Komamura, K., Kamakura, S., Kitakaze, M., Tomoike, H., Ueno, K., Goto, Y., Kimura, H., Katoh, M., Sugai, K., Saitoh, O., Kawai, M., Ohnuma, T., Ohtsuki, T., Suzuki, C., Minami, N., Kamatani, N., Ozawa, S. and Sawada, J. (2005) Single nucleotide polymorphisms and haplotypes of CYP1A2 in a Japanese population. Drug Metab. Pharmacokinet. 20, 24-33. https://doi.org/10.2133/dmpk.20.24
  18. Yun, C. H., Miller, G. P. and Guengerich, F. P. (2000) Rate-determining steps in phenacetin oxidations by human cytochrome P450 1A2 and selected mutants. Biochemistry 39, 11319-11329. https://doi.org/10.1021/bi000869u
  19. Zhou, H., Josephy, P. D., Kim, D. and Guengerich, F. P. (2004) Functional characterization of four allelic variants of human cytochrome P450 1A2. Arch. Biochem. Biophys. 422, 23-30. https://doi.org/10.1016/j.abb.2003.11.019

피인용 문헌

  1. Structural insights into the binding of lauric acid to CYP107L2 from Streptomyces avermitilis vol.482, pp.4, 2017, https://doi.org/10.1016/j.bbrc.2016.11.131
  2. Biochemical analysis of recombinant CYP4A11 allelic variant enzymes: W126R, K276T and S353G vol.31, pp.6, 2016, https://doi.org/10.1016/j.dmpk.2016.09.003
  3. In silico screening and analysis of nonsynonymous SNPs in human CYP1A2 to assess possible associations with pathogenicity and cancer susceptibility vol.11, pp.1, 2015, https://doi.org/10.1038/s41598-021-83696-x